Who is sponsoring NCT00276380?

NCT00276380 is sponsored by Ipsen.

What condition does NCT00276380 study?

NCT00276380 studies Stroke, Acute, Neurological Impairment.

What drugs are being tested in NCT00276380?

Interventions: EGb761, Placebo, Acetylsalicylic acid.

What is the status of NCT00276380?

NCT00276380 is currently COMPLETED.

Last reviewed 2019-01-04 · How we verify

A Phase III, Multicentre, Randomised, Double-blinded, Parallel Group, Placebo Controlled Clinical Study for Evaluating the Efficacy of EGb 761® (Tanakan®) (240mg) in the Recovery of Neurological Impairment Following Ischemic Stroke

NCT00276380 Phase 3 COMPLETED Results posted

The purpose of this study is to evaluate the effectiveness of Tanakan® 240mg in association with Acetylsalicylic acid (325mg/day) in the recovery of neurological impairment following ischemic stroke.

Details

Lead sponsor	Ipsen
Phase	Phase 3
Status	COMPLETED
Enrolment	204
Start date	2003-02
Completion	2009-03

Conditions

Stroke, Acute
Neurological Impairment

Interventions

EGb761
Placebo
Acetylsalicylic acid

Primary outcomes

Percentage of Subjects With Modified Rankin Score of Less Than 3 at the End of Study Period. — Day 168
The degree of disability and dependence in daily activities was assessed using the modified Rankin scale. The modified Rankin scale is a 6-point numerical scale (0=no symptoms at all, 1=no significant disability, 2=slight disability, 3=moderate disability, 4=moderately severe disability, 5=severe disability) which measures the degree of disability or dependence in the daily activities of people who have suffered a stroke. Assessments were made at baseline (Day 0) and at each follow-up visit on Day 28, Day 84 and Day 168. The percentage of subjects having a modified Rankin Score\<3 at the end of the study (Day 168) are reported.

Countries

Czechia, Poland, Romania, Russia